For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

Prostate cancer (PCa) is one of the most common malignant tumors in men worldwide. While early detection has improved patient outcomes, effective therapies for advanced disease remain limited.

Camcevi ETM, a long-acting injectable, is FDA-approved for advanced prostate cancer, showing 97.9% efficacy in testosterone suppression in a phase 3 study. Common side effects include hot flushing and ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...